Search

Your search keyword '"Carter, Lisa"' showing total 259 results

Search Constraints

Start Over You searched for: Author "Carter, Lisa" Remove constraint Author: "Carter, Lisa"
259 results on '"Carter, Lisa"'

Search Results

2. Research and Scholarship during the COVID-19 Pandemic: A Wicked Problem

6. Investing in health preparedness, response and resilience: a genomics costing tool focused on next generation sequencing

7. Investigating the role of the T-cell receptor using targeted capture and high-throughput sequencing

9. WHO's role in SARS-CoV-2 laboratory diagnostics: an end-to-end approach/Role de OMS dans le diagnostic en laboratoire de l'infection a SARS-CoV-2: une approche de bout en bout

10. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse

11. Strengthening pathogen genomic surveillance for health emergencies: insights from the World Health Organization’s regional initiatives

13. Supplementary Figure 3 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

14. Supplementary Figure 2 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

15. Supplementary Figure Legends from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

16. Supplementary Figure 4 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

17. Supplementary Table 2 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

18. Supplementary Figure 6 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

19. Supplementary Table 1 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

20. Supplementary Figure 1 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

21. Supplementary Figure 5 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells

22. New nomenclature for mpox (monkeypox) and monkeypox virus clades

24. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

26. Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022-2032

27. Academic Libraries on Social Media: Finding the Students and the Information They Want

29. Area Studies and Special Collections: Shared Challenges, Shared Strength

34. The Effects of Victim Gender Identity, Juror Gender, and Judicial Instructions on Victim Blaming, Crime Severity Ratings, and Verdicts in Sexual Assault Trials.

38. Real-time, portable genome sequencing for Ebola surveillance

39. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse [comment]

40. Long‐term effects of spasticity treatment, including selective dorsal rhizotomy, for individuals with cerebral palsy.

41. Abstract PS12-14: Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer

42. Abstract PS12-06: Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC)

43. WHO’s role in SARS-CoV-2 laboratory diagnostics: an end-to-end approach –Rôle de OMS dans le diagnostic en laboratoire de l’infection à SARS-CoV-2: une approche de bout en bout

45. Saving our legacy: Archiving television at the crossroads

50. A Feasibility Study Related To Inactive Cancer Survivors Compared with Non-Cancer Controls during Aerobic Exercise Training

Catalog

Books, media, physical & digital resources